Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer

Navjeet K. Gandhok, Stephen Warwick Looney, Shahriar Koochekpour, Oliver Sartor

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The detection of prostate-specific antigen (PSA) mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in the bloodstream of prostate cancer patients has been hypothesized as a prognostic marker, however little data are available concerning the association between this molecular marker and other laboratory values of potential importance. In this study, in patients with hormone-refractory prostate cancer (HRPC), relationships were determined between PSA RT-PCR positivity, survival, and various relevant markers including serum PSA, LDH, albumin, alkaline phosphatase and hemoglobin. A total of 19/30 HRPC patients were positive for PSA by RT-PCR. Positivity was significantly linked to serum PSA (P = 0.004) and serum alkaline phosphatase (P = 0.026) but not to the other laboratory variables. Median survival time for RT-PCR-positive patients was 9 months, compared to 19 months for RT-PCR-negative patients (P = 0.035). Median survival time for patients with a hemoglobin ≥11 g/dL was 12 months, compared to 9 months for patients with <11 g/dL (P = 0.005). Dichotomized (≥ or < median) serum PSA, LDH, alkaline phosphatase, and albumin were not significantly associated with survival in univariate analyses. In multivariate analysis, only dichotomized hemoglobin (<11g/dL vs. ≥11g/dL) remained statistically significant (P = 0.019), indicating that RT-PCR had no independent association with survival after controlling for hemoglobin status in this study.

Original languageEnglish (US)
Pages (from-to)163-167
Number of pages5
JournalUrologic Oncology: Seminars and Original Investigations
Volume23
Issue number3
DOIs
StatePublished - May 1 2005
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Reverse Transcriptase Polymerase Chain Reaction
Prostatic Neoplasms
Hormones
Survival
Hemoglobins
Alkaline Phosphatase
Albumins
Biomarkers
Serum
Multivariate Analysis
Messenger RNA

Keywords

  • Hormone refractory prostate cancer
  • PSA-mRNA
  • Prognosis
  • RT-PCR
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{3ec63c8a9c79421eb0930267fb6853bb,
title = "Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer",
abstract = "The detection of prostate-specific antigen (PSA) mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in the bloodstream of prostate cancer patients has been hypothesized as a prognostic marker, however little data are available concerning the association between this molecular marker and other laboratory values of potential importance. In this study, in patients with hormone-refractory prostate cancer (HRPC), relationships were determined between PSA RT-PCR positivity, survival, and various relevant markers including serum PSA, LDH, albumin, alkaline phosphatase and hemoglobin. A total of 19/30 HRPC patients were positive for PSA by RT-PCR. Positivity was significantly linked to serum PSA (P = 0.004) and serum alkaline phosphatase (P = 0.026) but not to the other laboratory variables. Median survival time for RT-PCR-positive patients was 9 months, compared to 19 months for RT-PCR-negative patients (P = 0.035). Median survival time for patients with a hemoglobin ≥11 g/dL was 12 months, compared to 9 months for patients with <11 g/dL (P = 0.005). Dichotomized (≥ or < median) serum PSA, LDH, alkaline phosphatase, and albumin were not significantly associated with survival in univariate analyses. In multivariate analysis, only dichotomized hemoglobin (<11g/dL vs. ≥11g/dL) remained statistically significant (P = 0.019), indicating that RT-PCR had no independent association with survival after controlling for hemoglobin status in this study.",
keywords = "Hormone refractory prostate cancer, PSA-mRNA, Prognosis, RT-PCR, Survival",
author = "Gandhok, {Navjeet K.} and Looney, {Stephen Warwick} and Shahriar Koochekpour and Oliver Sartor",
year = "2005",
month = "5",
day = "1",
doi = "10.1016/j.urolonc.2004.11.009",
language = "English (US)",
volume = "23",
pages = "163--167",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer

AU - Gandhok, Navjeet K.

AU - Looney, Stephen Warwick

AU - Koochekpour, Shahriar

AU - Sartor, Oliver

PY - 2005/5/1

Y1 - 2005/5/1

N2 - The detection of prostate-specific antigen (PSA) mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in the bloodstream of prostate cancer patients has been hypothesized as a prognostic marker, however little data are available concerning the association between this molecular marker and other laboratory values of potential importance. In this study, in patients with hormone-refractory prostate cancer (HRPC), relationships were determined between PSA RT-PCR positivity, survival, and various relevant markers including serum PSA, LDH, albumin, alkaline phosphatase and hemoglobin. A total of 19/30 HRPC patients were positive for PSA by RT-PCR. Positivity was significantly linked to serum PSA (P = 0.004) and serum alkaline phosphatase (P = 0.026) but not to the other laboratory variables. Median survival time for RT-PCR-positive patients was 9 months, compared to 19 months for RT-PCR-negative patients (P = 0.035). Median survival time for patients with a hemoglobin ≥11 g/dL was 12 months, compared to 9 months for patients with <11 g/dL (P = 0.005). Dichotomized (≥ or < median) serum PSA, LDH, alkaline phosphatase, and albumin were not significantly associated with survival in univariate analyses. In multivariate analysis, only dichotomized hemoglobin (<11g/dL vs. ≥11g/dL) remained statistically significant (P = 0.019), indicating that RT-PCR had no independent association with survival after controlling for hemoglobin status in this study.

AB - The detection of prostate-specific antigen (PSA) mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in the bloodstream of prostate cancer patients has been hypothesized as a prognostic marker, however little data are available concerning the association between this molecular marker and other laboratory values of potential importance. In this study, in patients with hormone-refractory prostate cancer (HRPC), relationships were determined between PSA RT-PCR positivity, survival, and various relevant markers including serum PSA, LDH, albumin, alkaline phosphatase and hemoglobin. A total of 19/30 HRPC patients were positive for PSA by RT-PCR. Positivity was significantly linked to serum PSA (P = 0.004) and serum alkaline phosphatase (P = 0.026) but not to the other laboratory variables. Median survival time for RT-PCR-positive patients was 9 months, compared to 19 months for RT-PCR-negative patients (P = 0.035). Median survival time for patients with a hemoglobin ≥11 g/dL was 12 months, compared to 9 months for patients with <11 g/dL (P = 0.005). Dichotomized (≥ or < median) serum PSA, LDH, alkaline phosphatase, and albumin were not significantly associated with survival in univariate analyses. In multivariate analysis, only dichotomized hemoglobin (<11g/dL vs. ≥11g/dL) remained statistically significant (P = 0.019), indicating that RT-PCR had no independent association with survival after controlling for hemoglobin status in this study.

KW - Hormone refractory prostate cancer

KW - PSA-mRNA

KW - Prognosis

KW - RT-PCR

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=19344363332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19344363332&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2004.11.009

DO - 10.1016/j.urolonc.2004.11.009

M3 - Article

C2 - 15907715

AN - SCOPUS:19344363332

VL - 23

SP - 163

EP - 167

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 3

ER -